---
figid: PMC6288394__fimmu-09-02869-g0001
figtitle: Summary of the potential mechanisms of vaccine NSEs
organisms:
- Escherichia coli
- Staphylococcus aureus
- Mycobacterium tuberculosis
- Mycobacterium tuberculosis variant bovis BCG
- Haemophilus influenzae
- Mycobacterium tuberculosis variant bovis
- Bordetella pertussis
- Staphylococcus aureus CI11
- H1N1 subtype
- Measles morbillivirus
- Variola virus
- Variola minor virus
- Bos taurus
- Canis lupus familiaris
- Sus scrofa
- Solanum tuberosum
- Candida albicans
- Vasconcellea candicans
- Homo sapiens
- Mus musculus
- Schistosoma mansoni
organisms_ner:
- Bos taurus
- Canis lupus familiaris
- Sus scrofa
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6288394
filename: fimmu-09-02869-g0001.jpg
figlink: /pmc/articles/PMC6288394/figure/F1/
number: F1
caption: Summary of the potential mechanisms of vaccine NSEs. (A) The top half illustrates
  adaptive mechanisms. Cross-reactive TCRs and antibodies. Lymphocyte antigen receptors
  recognize similar epitopes from different antigens. Bystander effect. Bystander
  activation of pre-existing effector or memory cells occurs via changes in the cytokine
  environment. Classical cell-mediated immunity. Adaptive immune cells potentiate
  the non-specific activity of innate cells in classical cell-mediated immunity. (B)
  The bottom half illustrates pathways of trained immunity. Primary stimulus of BCG.
  PRR signaling leads to TF activation, which then recruits chromatin modifiers to
  genes of interest. This stimulus also activate the autophagy and NOD2 signaling
  pathway. Upregulation of the Akt/mTOR pathway alters metabolite levels that regulate
  chromatin-modifying enzymes. Heterologous secondary stimulus. Epigenetic changes
  within innate cells after training act as de novo enhancers to boost the immune
  response against a secondary challenge.
papertitle: 'Non-specific Effects of Vaccines Illustrated Through the BCG Example:
  From Observations to Demonstrations.'
reftext: Deeva Uthayakumar, et al. Front Immunol. 2018;9:2869.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8783737
figid_alias: PMC6288394__F1
figtype: Figure
redirect_from: /figures/PMC6288394__F1
ndex: 37abc8a5-df1a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6288394__fimmu-09-02869-g0001.html
  '@type': Dataset
  description: Summary of the potential mechanisms of vaccine NSEs. (A) The top half
    illustrates adaptive mechanisms. Cross-reactive TCRs and antibodies. Lymphocyte
    antigen receptors recognize similar epitopes from different antigens. Bystander
    effect. Bystander activation of pre-existing effector or memory cells occurs via
    changes in the cytokine environment. Classical cell-mediated immunity. Adaptive
    immune cells potentiate the non-specific activity of innate cells in classical
    cell-mediated immunity. (B) The bottom half illustrates pathways of trained immunity.
    Primary stimulus of BCG. PRR signaling leads to TF activation, which then recruits
    chromatin modifiers to genes of interest. This stimulus also activate the autophagy
    and NOD2 signaling pathway. Upregulation of the Akt/mTOR pathway alters metabolite
    levels that regulate chromatin-modifying enzymes. Heterologous secondary stimulus.
    Epigenetic changes within innate cells after training act as de novo enhancers
    to boost the immune response against a secondary challenge.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LOC505306
  - TARP
  - IL1B
  - IL6
  - TNF
  - MTOR
  - AKT1
  - HIF1A
  - NOD2
  - JUN
  - IL1B2
  - IL-6
  - Eno2
  - Trav6-3
  - Hand1
  - Nelfcd
  - Il1b
  - Il6
  - Tnf
  - Slc11a1
  - Mtor
  - Akt1
  - Jun
  - Nfkb1
  - Hif1a
  - Gnat2
  - Nod2
  - .na.character
  - ENO2
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - NELFCD
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - AKT2
  - AKT3
  - FOS
  - FOSB
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - Tcr
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - TH1
  - egr
  - 18w
  - tok
  - tlr-2
  - 'On'
  - Tor
  - Akt
  - AP-1gamma
  - Jra
  - kay
  - Dif
  - dl
  - Rel
  - sima
  - CycE
  - cyc
  - Low
  - TCR
  - Cholesterol
  - mevalonate
  - Citrate
  - TSA
  - Cancer
---
